^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Columvi (glofitamab-gxbm)

    i
    Other names: RG6026, RO7082859, CD20 TCB, RG 6026, RO-7082859, RO 7082859, anti-CD20 CD3 TCB, RG-6026
    Company:
    Biogen, Roche
    Drug class:
    CD20 inhibitor, CD3 agonist
    Related drugs:
    2d
    Radio-GLO: Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Olivia Newton-John Cancer Research Institute
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1) • IL4 (Interleukin 4)
    |
    Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm)
    6d
    REBEL: External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL (clinicaltrials.gov)
    P1, N=12, Recruiting, University of Utah | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Epkinly (epcoritamab-bysp) • Columvi (glofitamab-gxbm)
    7d
    Glofitamab in Real Life (clinicaltrials.gov)
    P=N/A, N=250, Recruiting, The Lymphoma Academic Research Organisation | Trial completion date: Jul 2026 --> Dec 2026
    Trial completion date
    |
    Columvi (glofitamab-gxbm)
    12d
    Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    TP53 (Tumor protein P53)
    |
    Gazyva (obinutuzumab) • cyclophosphamide • fludarabine IV • Columvi (glofitamab-gxbm)
    15d
    UPCC 48420: CAR-T Followed by Bispecific Antibodies (clinicaltrials.gov)
    P2, N=23, Recruiting, Abramson Cancer Center at Penn Medicine | N=42 --> 23
    Enrollment change
    |
    Gazyva (obinutuzumab) • Lunsumio (mosunetuzumab-axgb) • Columvi (glofitamab-gxbm)
    16d
    Case Report: Neurolymphomatosis of the sciatic nerve as a presentation of relapsed diffuse large B-cell lymphoma. (PubMed, Front Oncol)
    A 71-year-old man with systemic diffuse large B-cell lymphoma (DLBCL), histologically confirmed by gastric biopsy, developed progressive left-leg neuropathic pain, numbness, and foot drop during rituximab maintenance after achieving complete remission (CR)...Given the patient's age and risk of neurotoxicity, treatment with cyclophosphamide preconditioning followed by glofitamab plus obinutuzumab achieved rapid clinical improvement and partial remission (PR) on imaging...In this case, nerve US played a central role by demonstrating the characteristic "fried egg sign," localizing the lesion, and enabling US-CNB for tissue confirmation, while contrast-enhanced MRI and whole-body ^18F-FDG PET/CT provided complementary information on neural involvement and overall disease extent. An ultrasound-centered multimodal approach may help shorten time to diagnosis and facilitate timely treatment and neurological recovery.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • Gazyva (obinutuzumab) • cyclophosphamide • Columvi (glofitamab-gxbm)
    18d
    LME-Guided Precision Combination Therapy in B-cell Lymphoma Patients After CD19 CAR-T Failure (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Venclexta (venetoclax) • Tevimbra (tislelizumab-jsgr) • Columvi (glofitamab-gxbm)
    21d
    A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=96, Not yet recruiting, The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    gemcitabine • Gazyva (obinutuzumab) • oxaliplatin • Columvi (glofitamab-gxbm)
    22d
    GUIDANCE-10: AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL (clinicaltrials.gov)
    P2, N=178, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib) • decitabine • prednisone • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
    24d
    TP53 mutations and baseline lymphocytes indicate response to glofitamab in relapsed or refractory diffuse large B-cell lymphoma. (PubMed, Ann Hematol)
    This study demonstrates that glofitamab is effective and well-tolerated in Chinese R/R DLBCL patients. Earlier lines of glofitamab may be more beneficial, while expanded cohorts are warranted to explore its efficacy among patients with multiple extranodal lesions, TP53 mutations and low baseline lymphocytes.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Columvi (glofitamab-gxbm)
    24d
    CD20 re-emergence in a patient with diffuse large b-cell lymphoma who experienced a CD20-negative relapse after glofitamab treatment. (PubMed, Haematologica)
    Not available.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 negative
    |
    Columvi (glofitamab-gxbm)
    27d
    GLOHRT-01: Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden (clinicaltrials.gov)
    P2, N=40, Recruiting, Liling Zhang | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
    |
    CD20 positive
    |
    Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm)